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Abstract: Heart failure is a relatively important public health problem due to its increasing
incidence, poor prognosis, and frequent need of re-hospitalization. Intravenous positive
inotropic agents play an important role in treating acute decompensation of patients with
heart failure due to left ventricular systolic dysfunction. Although frequently used, the inotropic
agents β-adrenergic agonists and phosphodiesterase inhibitors seem effective for improving
symptoms in the short term; it has been shown that they increase morbidity and mortality by
elevating intracellular cyclic adenosine monophosphate (cAMP) and calcium levels.
Levosimendan is a new positive inotropic agent having ATP-dependent potassium-channel-
opening and calcium-sensitizing effects. In studies on its effects without increasing intracellular
calcium concentrations and on its effects that depend on available intracellular calcium levels,
it has been shown to have favorable characteristics different from those of current inotropic
agents, which exert their effects by increasing calcium concentrations. This study aims to
review other important studies about levosimendan by revealing the underlying mechanisms
of its activity, efficiency, and safety.
Keywords: heart failure, positive inotropic therapy, levosimendan
Introduction
Heart failure is a growing problem for both individuals and public health especially
as the elderly population is increasing (McKee et al 1971; Mosterd et al 1999).
According to the World Health Organization, it is estimated that there are 22.6 million
heart failure patients worldwide (McMurray et al 2000; Cleland et al 2001). Especially,
in European countries, myocardial dysfunction due to coronary heart disease is the
most frequent reason for heart failure in patients under the age of 75 (Sutton 1990).
Moreover, regardless of the underlying cause, the prognosis of heart failure patients
is relatively poor. For example, nearly 40% of severe heart failure patients die within
a year of acute exacerbation (Cowie et al 2000). Furthermore, it is a relatively
important public health problem with respect to re-hospitalization and prolonged
hospitalization frequency.
In the treatment of acute decompensation of heart failure caused by left systolic
dysfunction, intravenous positive inotropic agents are playing an important role in
eliminating hemodynamic abnormalities and improving symptoms (Cowie et al 2000;
Slawsky et al 2000).
Indeed, currently the most used intravenous inotropic agents in clinical practice
include β-adrenergic agonists and phosphodiesterase inhibitors. β-adrenergic receptor
agonists trigger calcium influx into the myocytes by increasing intracellular cAMP
levels through cyclic adenosine monophosphate (cAMP) production.
Phosphodiesterase inhibitors do the same thing by inhibiting its degradation (Colucci
et al 1986; Cody 1988; Packer 1993). Increased intracellular calcium levels increase
cellular energy need, resulting in an increase of myocardial oxygen consumption
(Colucci et al 1986; Slawsky et al 2000). Moreover, it is reported that increased
intracellular cAMP and Ca
+ concentration are cardiotoxic (Lee and Downing 1980;
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Stevenson 1998). Elevated intracellular calcium
concentrations trigger arrhythmias by affecting myocytes’
electrophysiology (Packer and Leier 1987; Ferric et al 1990).
As a result, this condition further increases cellular energy
need and myocardial oxygen consumption (Hasenfuss et al
1989; Haikala et al 2000). Although these agents seem useful
during the acute exacerbation of heart failure in the short
term, it was reported that they cause progression in and
increased mortality from the disease (Dies et al 1986; Ferrick
et al 1990; Felker et al 2003; Abraham et al 2005).
Thus, in the meantime, attention is focused on the
calcium-sensitizing agents that enhance cardiac performance
without increasing intracellular calcium and cAMP levels.
Among these groups of agents, levosimendan and
pimobendan are known as calcium sensitizers that are
available for clinical practice.
Mechanism of action
Levosimendan has a dual mechanism of action: (1) This
agent sensitizes troponin C to calcium in a manner dependent
on the calcium concentration, thereby increasing the effects
of calcium on cardiac myofilaments during systole and
improving contraction at low energy cost (Hasenfuss et al
1998; Janssen et al 2000). (2) During diastole, sensitization
is diminished due to a plunge in calcium concentration level
which does not cause a deterioration of diastolic relaxation
but, on the contrary, does cause an improvement (Pagel et
al 1997; Janssen et al 2000; Tachibana et al 2005). Since
levosimendan does not cause any diastolic calcium overload,
unlike other inotropic agents, it is also does not cause any
cardiac myocyte dysfunction, arrhythmia, or an increase of
energy consumption (Hasenfuss et al 1995). The enhanced
calcium myofilament responsiveness mediated by
levosimendan results in increased cross bridge formation
and greater contractility. Because levosimendan-enhanced
cross bridge formation depends on the presence of calcium,
there is no impairment of myocardial relaxation during
diastole (Haikala and Linden 1995; Gheorghiade et al 2005).
In addition, preclinical studies indicate that levosimendan
may enhance myocardial relaxation and diastolic function
(Gheorghiade et al 2005; Tachibana et al 2005).
Moreover, levosimendan also opens ATP-dependent
potassium (K) channels in myocytes and vascular smooth
muscle cells, which results in vasodilatation (Yokoshiki et
al 1997; Pataricza et al 2000; Kaheinen et al 2001). This
reduces preload and afterload, and increases coronary and
other organ blood flow (Harkin et al 1995; Yokoshiki and
Sperelakis 2003; Michaels et al 2005).
Cardio protective effect
During the acute exacerbation of heart failure, accelerated
cellular loss occurs due to deterioration of ischemia,
mechanical strain, neurohormones production, inflammation
and oxidative stress, and progressive myocardial failure. It
is suggested that on these patients, levosimendan exerts its
cardio protective effect by activation of ATP-dependent K
(KATP) channels which inhibit mitochondrial apoptotic
pathway (Maytin and Colluci 2005).
Furthermore, in a study by Nieminen et al (2000), it was
shown that levosimendan did not increase troponin T levels
which were manifestations of myocardial injury. In addition
to its well-described hemodynamic effects, levosimendan
also activates KATP channels both in plasma membrane and
in mitochondrial matrix of cardiac myocytes (Maytin and
Colluci 2005; Kopustinskiene et al 2001). It is now
recognized that the activation of mitochondrial KATP
channels in cardiac myocytes is an important and potent
cardio protective mechanism (O’Rourke 2004). Apoptosis
is an energy-dependent process mediated by a highly
organized biochemical cascade. Although ischemia is an
important cause of apoptosis, several additional apoptotic
stimuli, including oxidative stress, mechanical strain, and
neurohormones (eg, norepinephrine and angiotensin) have
been identified and are believed to contribute to progressive
myocyte loss during chronic heart failure (Rossig et al 2004;
Maytin and Colluci 2005).
Anti-inflammatory effect
It has been reported that elevated circulatory levels of pro-
inflammatory cytokines (TNF-α, IL-6, and IL-1β) increase
the apoptosis of cardiac myocytes and endothelial cells by
increasing oxidative stress and lead to the suppression of
myocardial contractility, and that they have a role in the
clinical and hemodynamic deterioration of heart failure (Seta
et al 1996; Sasayama et al 1999).
 Elevated levels of TNF-α
and IL-6 have been associated with increased morbidity and
mortality in patients with advanced heart failures (Levine
et al 1990; Torre-Amione et al 1996; Tsutamoto 1998; Plenz
et al 2001). Recent studies show that therapies that decrease
cytokine levels may improve the clinical picture and
ventricular functions in patients with congestive heart failure
(Gullestad et al 2001; Skudicky et al 2001).
Some other studies indicate that levosimendan exerts
anti-apoptotic and anti-inflammatory effects by decreasing
the circulatory pro-inflammatory cytokines and solubleVascular Health and Risk Management 2006:2(4) 391
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apoptosis mediators (Parissis et al 2004; Avgeropoulou et
al 2005; Kyrzopoulos et al 2005).
Effects on matrix
metalloproteinase
It has been concluded that levosimendan decreases the levels
of matrix metalloproteinases, which regulate extracellular
matrix metabolism, and play an important role in the left
ventricular remodeling in chronic heart failure (McMurray
and Pfeffer 2002; Tziakas et al 2005). Therefore, it is
suggested that levosimendan may show pleiotropic effects
that may affect myocardial remodeling (Tziakas et al 2005).
Neurohormonal effect
It is known that neurohormonal changes occur in acute heart
failure and strong vasoconstrictors, epinephrine and
norepinephrine, are increased as a response to the decreased
cardiac output. In fact, increased epinephrine and
norepinephrine levels are prognostic markers showing a
decrease in survival rates (Cohn et al 1984; Kaye et al 1995;
Bristow et al 2004). Also, it has been shown that
levosimendan in therapeutic dosages does not increase
epinephrine and norepinephrine concentrations (Nicklass
et al 1999; Nieminen et al 2000). In addition, it has been
determined that levosimendan decreases plasma endotelin-
1 concentrations in patients with severe heart failure (Nicklas
et al 1999).
B type natriuretic peptide level (BNP) is one of the best
prognostic markers in heart failure. It has been demonstrated
that during treatment of decompensated chronic heart failure,
the changes in BNP levels were strongly predictive for
mortality and early re-hospitalization (Cheng et al 2001). It
has been proved that levosimendan leads to a marked
decrease in BNP levels and supports clinical improvement
in these patients (Avgeropoulou et al 2005; Kyrzopoulos et
al 2005; Moertl et al 2005; Parissis et al 2005).
Effects on coronary circulation
It has been determined that administration of intravenous
levosimendan has a direct vasodilator effect on conductance
and resistance of coronary arteries (Gruhn et al 1998). It
has been suggested that levosimendan exerts this effect by
opening ATP-sensitive K channels in vascular smooth
muscles (Gruhn et al 1998; Kaheinen et al 2001). It has
been demonstrated that coronary artery flow was increased
and coronary artery resistance was reduced during
levosimendan infusion (Michaels et al 2005).
Also, in another study conducted with positron emission
tomography imaging in heart failure patients, levosimendan
increased myocardial blood flow compared to placebo
(Ukkonen et al 2000).
In a study by De Luca et al (2005) on patients with LV
dysfunction following myocardial infarction just after
primary percutaneous coronary intervention, it was
determined that levosimendan infusion improved
hemodynamic parameters and coronary flow reserve.
Anti-stunning effect
Abnormal calcium homeostasis and decreased sensitivity
of contractile proteins against calcium are important factors
for the development of myocardial stunning (Bolli 1990;
Bolli and Marban 1999). Therefore, it is suggested that
calcium-sensitizing agents may improve the functions of
stunned myocardium (Soei et al 1994). To clarify, Sonntag
et al (2004), in a study in which the patients undergoing
angioplasty following acute coronary syndrome were
examined, showed that levosimendan improved systolic
performance of the stunned myocardium without worsening
diastolic functions.
Hemodynamic effects/influence on
systolic function/influence on
diastolic function
Although levosimendan causes vasodilatation by opening
ATP-dependent K channels in vascular smooth muscle cells,
this does not only result in a reduction of preload and
afterload but it also creates a positive inotropic effect (Harkin
et al 1995). It was determined in multicenter large scale
studies conducted on patients with heart failure that
levosimendan reduced pulmonary capillary wedge pressure
(PCWP), right atrial, pulmonary arterial and mean arterial
pressures, and peripheral vascular resistance (PVR), whereas
it increased cardiac index (Nieminen et al 2000; Slawsky et
al 2000; Follath et al 2002).
As is the case with other drugs having potent vasodilator
activity, levosimendan increases intrapulmonary shunting.
However, in contrast to these drugs, it does not reduce
arterial oxygen saturation (Lilleberg et al 1998).
In a study by Sonntag et al (2004) with patients
undergoing percutaneous transluminal
 coronary angioplasty
due to acute coronary syndrome, levosimendan infusion
after 10 minutes following successful intervention reduced
the number of hypokinetic segments. As an indicator of
improved systolic functions, increase of ejection fraction,
and decrease of end diastolic volume, single-beat elastance,Vascular Health and Risk Management 2006:2(4) 392
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and upward/leftward shift of the systolic part of the pressure–
volume
 loop have been observed.
One of the most important indicators of improved
contractile functions with levosimendan infusion is the
increase in exercise capacity. In a tissue Doppler
echocardiography study conducted by Kasikcioglu et al
(2005), there was a significant increase in the exercise
capacity assessed by 6 minute walking test parallel to the
increase of systolic myocardial velocity for mitral annulus
as an indicator of the increase in contractile functions.
Calcium-sensitizing agents may not have negative effects
on diastolic functions although they improve systolic
function by increasing the affinity of troponin C to calcium
both in systole and diastole (Haikala and Linden 1995).
Sensitization is calcium-concentration dependent;
sensitization of contractile apparatus is done in systole but
not in diastole. This leads to an inotropic effect without
impairing diastolic relaxation (Hasenfuss 1998; Haikala and
Pollesello 2000; Cleland et al 2004; Sonntag et al 2004).
Indeed, unlike the effects of other calcium sensitizers, the
effect of levosimendan is dependent on intracellular calcium
levels, and it does not worsen diastolic functions even though
there are studies showing its positive effects on diastolic
functions (Haikala et al 1995; Sonntag et al 2004;
Kasikcioglu et al 2005; Parissis et al 2005). Also,
levosimendan decreases the index of diastolic relaxation,
indicating that levosimendan seems to improve the systolic
performance of stunned myocardium without impairing
diastolic function (Hasenfuss 1998; Haikala and Pollesello
2000; Sonntag et al 2004; De Luca et al 2006)
Anti-arrhythmic effect
Another study, in which the patients with normal cardiac
functions were examined, showed that levosimendan
shortened atrial, atrioventricular node, and ventricular
effective refractory period (Toivonen et al 2000). On patients
with atrial fibrillation, it is reported that levosimendan may
not only increase ventricular rate by accelerating
atrioventricular conduction but it may also induce an
increase in heart rate by shortening the sinus node recovery
time (Toivonen et al 2000). Although it has no influence on
the uncorrected QT interval it is reported that it may prolong
corrected QT interval in doses higher than the therapeutic
levels (Singh et al 1999).
Ambulatory electrocardiographic and electro-
physiological evaluation did not detect any pro-arrhythmic
effect of intravenous levosimendan (Singh et al 1999). On
the other hand, the REVIVE study showed that the rate of
ventricular tachycardia, atrial fibrillation, and ventricular
extra-systoles in the levosimendan group were increased
compared with placebo (Packer et al 2005).
Pharmacokinetics and metabolism
Levosimendan has an elimination half-life of 1 hour
(Kivikko et al 2002a, 2002b). However, the half-lives of its
two circulating metabolites, OR-1855 and its acetylated form
OR-1896, range between 70 and 80 hours (Kivikko et al
2002a, 2002b). These metabolites reach their maximum
serum concentration 2 days after completion of a 24-hour
intravenous levosimendan infusion (Sundberg et al 1998).
Since the OR-1896 metabolite is hemodynamically active,
with properties similar to those of levosimendan, the
hemodynamic effects of levosimendan should theoretically
persist for at least 7–10 days following the intravenous
infusion (Kivikko et al 2002a, 2002b).
Combinations with other drugs
It was demonstrated that the combination of levosimendan
and dobutamine is relatively safe and effective on patients
with severe heart failure (Nanas et al 2004, 2005). It can be
combined with norepinephrine in patients with initially low
systolic blood pressure to maintain adequate organ and tissue
perfusion (Delle Karth et al 2003; Lehmann et al 2004).
Although beta blocker use decreases the inotropic and
vasodilator effects in patients taking dobutamine, no
reduction in levosimendan level was reported (Follath et al
2002). It is reported that concomitant use of levosimendan
with angiotensin-converting enzyme inhibitors and nitrates
may increase the hypotension and tachycardia effects of
levosimendan (Antila et al 1996; Sundberg et al 2000)
Clinical studies
The studies demonstrate that the efficacy and safety of
levosimendan and are important and guiding factors for the
current clinical practice. The results are summarized in Table
1.
A multicenter, placebo-controlled, randomized study
conducted by Nieminen et al (2000) to determine the
therapeutic dose range of levosimendan enrolled 151
patients with New York Heart Association (NYHA) class
II-IV heart failure with ischemic origin. Five different dose
regimes of levosimendan (10-minute loading dose of 3, 6,
12, 24, or 36 µg kg-1 followed by a 24-hour infusion of 0.05,Vascular Health and Risk Management 2006:2(4) 393
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0.1, 0.2, 0.4, or 0.6 µg kg-1 min-1) were compared with
placebo and dobutamine (6 µg kg
-1 min
-1). When all
levosimendan groups were evaluated, it was determined that
reported hemodynamic targets were attained in more than
50% of the patients. At all doses of levosimendan, response
rates were significantly greater than those of placebo
(p=0.038 at the lowest dose and p≤0.005 at all other doses).
This study concluded that 6–24 µg kg
-1 loading dose of
levosimendan for 10 minutes followed by 0.05–0.2 µg kg
-1
min
-1 infusion was well tolerated, with favorable
hemodynamic effects.
A multicenter, double-blind, placebo-controlled,
randomized study conducted by Slawsky et al (2000), with
the objective of determining the short-term hemodynamic
and clinical effects of levosimendan, enrolled 146 NYHA
class III-IV heart failure patients with pulmonary capillary
wedge pressure ≥15 mmHg and a cardiac
 index of
≤2.5 L min
-1 m
-2. In this study, patients were randomized 2:1
to receive intravenous levosimendan
  or placebo.
Levosimendan was initiated as a bolus of 6 µg kg
-1,
 followed
by a continuous infusion, initially at a rate of 0.1 µg kg
-1
min-1. At hourly intervals, a repeat bolus (6 µg kg-1) was
given and the infusion rate was increased
 by increments of
0.1 µg kg
-1. Uptitration was continued
 until a maximum dose
of 0.4 µg kg-1 min-1 was achieved or until a dose-limiting
event occurred. Patients were administered 6-hour infusions
and hemodynamic measurements were obtained at baseline,
at the end of each hourly uptitration for hours 1–4, and at
hours 5.5 and
 6. The symptoms of
 dyspnea and fatigue were
evaluated by the patient and the physician at
 baseline and at
the sixth hour. Levosimendan was associated with dose-
dependent increases in stroke volume and cardiac index that
were significantly different from the effects of placebo at
all doses tested. In addition, levosimendan was associated
with dose-dependency, which significantly decreased PCWP
at all doses. Assessments of dyspnea and fatigue at the sixth
hour demonstrated that levosimendan was associated with
significantly improved dyspnea and a trend towards
improved fatigue. The results of this study showed that
levosimendan causes a rapid dose-dependent improvement
in hemodynamic functions and in clinical picture without
any significant increase in adverse events in patients with
decompensated heart failure.
After completion of 6-hour infusions, 85 patients were
completely infused as open label for 24 hours and the
patients were randomized 1:1 in a double-blind manner. In
one group, the infusion was discontinued and then
maintained with placebo whereas levosimendan was
maintained for 24 hours in the other group (Kivikko et al
2003). The objective of this study was
 to determine whether
the hemodynamic effects of levosimendan were sustained
during a long-term infusion and beyond the discontinuation
of
 infusion. At the conclusion of the study, it was
demonstrated that hemodynamic effects continued at least
24 hours after 24-hour infusion. A series of adverse events
may be seen in infusions prolonged for more than 24–
48 hours due to excess metabolite accumulation, and the
24-hour duration is safe and effective.
The Levosimendan Infusion versus Dobutamine in
severe low-output heart failure (LIDO) study is a
multicenter, double-blind, double-dummy, randomized
study in low-output heart failure patients. It was designed
to compare the clinical and hemodynamic effects of
levosimendan and dobutamine (Follath et al 2002). A total
of 203 patients with severe low-output heart failure (left
ventricular ejection fraction [LVEF] <0.35, cardiac index
(CI) <2.5 L min-1 m-2, and PCWP<15 mmHg) were included
in the study. A levosimendan 24 µg kg
-1 loading dose is
maintained with a 24-hour infusion with 0.1 µg kg
-1 min
-1
dose. Dobutamine was administered in 5 µg kg-1 min-1 dose.
Infusion rates were doubled after 2 hours on 69 patients
randomized to levosimendan and on 40 patients randomized
to dobutamine whose cardiac output had not risen by more
than 30%. Among the doses used in this study, the cardiac-
output-enhancing effect (29% increase over baseline for
levosimendan compared with a 22% increase for
dobutamine, p=0.05) and PCWP-lowering effect of
levosimendan (28% decrease over baseline for
levosimendan compared with a 13% decrease for
dobutamine, p=0.03) were greater than those of dobutamine.
In this study, it was shown that 6 hours after the infusion
had been completed, the effects of levosimendan were still
continuing whereas dobutamine hemodynamic effects had
disappeared. Clinical symptoms of dyspnea and fatigue
tended to improve more with levosimendan than they did
with dobutamine but these differences were not significant.
It was also demonstrated that 180-days mortality was
lower in the levosimendan group compared with dobutamine
group (mortality rate in levosimendan and dobutamine
patients were 26% and 38% respectively, p=0.029).
The Randomized Study on Safety and Effectiveness of
Levosimendan in Patients with Left Ventricular Failure Due
to an Acute Myocardial Infarct (RUSSLAN) evaluated
different doses of levosimendan versus placebo in subjects
with heart failure following an acute myocardial infarction
(Moiseyev et al 2002). This study was double-blind andVascular Health and Risk Management 2006:2(4) 394
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placebo-controlled. This is the first and the largest study,
conducted with 504 patients comprising four different
levosimendan dose groups and a placebo group. No
significant differences among the five treatment groups were
observed in the proportion of patients experiencing
hypotension or ischemia (primary endpoint). Nonetheless,
a greater incidence of arterial hypotension and ischemia was
observed among patients who received the highest doses of
levosimendan (bolus, 24 µg kg
-1; infusion, 0.4 µg kg
-1
min
-1) compared with the patients who received the highest
doses of placebo. In 14 days, the mortality rate in the
levosimendan group was 11.7% compared with 19.6% in
the placebo group (p=0.03). However, there was no
statistically significant difference between two dose groups
in terms of 180-day mortality (p=0.053). In this study,
although there is no significant improvement in patients’
complaints during levosimendan infusion periods, the
worsening of heart failure in 6 hours (p=0.033) and in 24
hours (p=0.044) were significantly less when compared with
those of placebo group.
The Calcium Sensitizer or Inotrope or None in Low-
Output Heart Failure Study (CASINO) is a randomized,
double-blind, double-dummy, and parallel-group study
(Zairis et al 2004). This study was designed to compare the
safety and efficacy of levosimendan, dobutamine, and
placebo on patients with decompensated heart failures.
Patients with NYHA class IV heart failure and LVEF ≤35%
were recruited for the study in which levosimendan,
dobutamine, or placebo infusions were administered. The
study was originally designed to recruit 600 patients;
however, it was stopped prematurely after 299 patients had
been enrolled, due to a clear mortality benefit in favor of
the levosimendan group. Levosimendan showed a
significant survival benefit on these patients whereas
dobutamine appeared to increase mortality. After 1 month,
the mortality rates were 6.1% for levosimendan (p=0.1
compared with placebo and p=0.04 compared with
dobutamine), 12.8% for dobutamine, and 8.2% for placebo
treatment. After 6 months, the mortality rates were 15.3%
for levosimendan (p=0.0001 compared with dobutamine and
p=0.04 compared with placebo), 39.6% for dobutamine, and
24.7% for placebo treatment. However, it should be noted
that these data have not yet been published by a peer-
reviewed journal.
The Randomized Multicenter Evaluation of Intravenous
Levosimendan Efficacy Versus Placebo in the Short-Term
Treatment of Decompensated Heart Failure (REVIVE) was
a double-blind, placebo-controlled, large-scale study (Packer
et al 2005). Patients with acute decompensated heart failure,
LVEF<35%, and having resting dyspnea despite intravenous
diuretics were included in this study. Patients were
randomized to receive either a levosimendan bolus (6–
12 µg kg
-1) followed by a stepped dose regimen of
levosimendan (0.1–0.2 µg kg
-1 min
-1) for 24 hours plus
standard therapy, or a placebo infusion for 24 hours plus
standard therapy. The REVIVE-1 study is the pilot study
consisting of the first 100 patients of this study. This pilot
study was designed to compare the intensive care unit and
hospital stays between levosimendan and placebo groups
and to test the feasibility of clinical composite endpoint
instead of hemodynamic measurement which was employed
as an endpoint in previous studies in this patient group
(Garrat et al 2004; Johansson et al 2004). This study
concluded that for the patients with acute heart failures, the
intensive care unit stay in levosimendan group is 1 day
shorter than that of the standard treatment group. This clearly
shows that the hospitalization costs may be reduced by
adopting levosimendan treatment.
After the completion of the REVIVE-1 enrollment, the
REVIVE-2 study enrolled 600 patients (Packer et al 2005).
The objective of new endpoints used in this study is to detect
the alterations of patients’ symptoms and clinical conditions.
Thus, the patients were divided in three groups as worsening,
stable, and improving according to their clinical picture. In
this study, on the fifth day 33% more patients in the
levosimendan group had improved and 30% fewer of them
had worsened compared with patients in the control group
(p=0.015 for both differences). Worsening acute heart failure
requiring rescue intravenous therapy developed in 15% of
patients in the levosimendan group and 26% of patients in
the control group. The secondary endpoint of 90-day all-
cause mortality rate was 15.1% in the levosimendan group
and 11.6% among other control groups.
The Survival of Patients with Acute Heart Failure in
Need of Intravenous Inotropic Support Study (SURVIVE)
is a randomized, double-blind, double-dummy, prospective,
controlled study (Mebazaa 2005; Mebazaa et al 2005). A
total of 1327 patients hospitalized for acute decompensated
heart failure, LVEF≤30%, not responding to intravenous
diuretics and vasodilator therapy were included in the study.
The primary endpoint of SURVIVE was all-cause mortality
in 180 days, and the study was also designed to demonstrate
a 25% lower mortality rate in the levosimendan group than
that of the dobutamine group, following a single intravenous
infusion. This study is the first trial using mortality as the
primary endpoint in evaluating the efficacy (Mebazaa 2005;Vascular Health and Risk Management 2006:2(4) 397
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Mebazaa et al 2005). Secondary endpoints for this trial
include the number of days alive and out of the hospital
during the 180 days of the trial, all-cause mortality during
31 days, cardiovascular mortality during 180 days, and
global assessment at 24 hours. Patients were randomized to
either dobutamine (minimum dose 5 µg kg
-1 min
-1) or
levosimendan bolus (12 µg kg
-1) followed by a stepped dose
regimen of levosimendan (0.1–0.2 µg kg
-1 min
-1). Both
treatment groups also received standard care. After 5 days,
2 weeks, 1 month, and 6 months following the study drug
infusion, mortality rate in the levosimendan group was
reduced by 27%, 14%, 13%, and 6.4%, respectively,
compared with that of the dobutamine group. These
differences did not reach statistical significance. A secondary
endpoint of BNP was significantly reduced in the
levosimendan arm compared with the dobutamine arm.
Tolerability
Levosimendan is generally well tolerated. Most of its
adverse effects are dose-related and due to its vasodilator
effect (Lehtonen et al 1995). The most frequent adverse
events associated with levosimendan include headache
(5%), hypotension (5%), dizziness (1%–10%), and nausea
(1%–10%) (Nieminen et al 2000; Slawsky et al 2000; Follath
et al 2002; Moiseyev et al 2002; Sandel et al 2004). Among
laboratory parameters, slight decreases of red blood cell
count, hematocrit, and hemoglobin (10%), and, particularly
in higher doses group, a slight decrease of serum K levels
have been reported (Nieminen et al 2000). Serum creatinine
levels were affected positively even among the patients with
baseline renal function impairment (Follath et al 2002;
Franco et al 2003).
Overall, studies demonstrated that levosimendan did not
deteriorate or trigger myocardial ischemia (Follath et al
2002). However, excess reductions of blood pressure may
decrease coronary perfusion pressure and provoke ischemia
(Cleland et al 2004).
Although less arrhythmia was reported in clinical studies
comparing levosimendan and dobutamine with placebo,
ventricular tachycardia (25% vs 17%) and atrial fibrillation
(8% vs 2%) were more frequent in the levosimendan group
compared with the standard treatment group in the REVIVE
II study (Nieminen et al 2000; Follath et al 2002; Moiseyev
et al 2002; Packer et al 2005). In the SURVIVE study, atrial
fibrillation (9.1% vs 6.1%) and ventricular tachycardia
(7.9% vs 7.3%) were more frequent in the levosimendan
group compared with the dobutamine group (Mebazaa
2005).
Dose recommendations
If rapid onset of action is desired, 6–24 µg kg-1 min-1 is
administered in 10–20 minutes according to the clinical
picture of the patient. In patients with systolic blood pressure
<90 mmHg, a loading dose should be avoided. An optimum
maintenance dose of 0.05–0.2 µg kg
-1 min
-1 is recommended.
In doses above 0.2 µg kg
-1 min
-1, adverse events may be seen
more frequently (Moiseyev et al 2002). Since the half-life
of its metabolites is longer, it was shown that the
accumulation of metabolites during prolonged infusions
enhances the adverse events. Therefore, infusions longer
than 24 hours are not recommended (Kivikko et al 2003).
Place in clinical practice
Clinical studies have show that the use of levosimendan is
safe and effective in postponing heart failure and in heart
failure following acute myocardial infarction (Moiseyev et
al 2002; Sonntag et al 2004). Although some studies have
shown that levosimendan may be used in patients with
shock, acute heart failure guidelines published by the
European Society of Cardiology recommend its use on
patients having symptomatic, low-output heart failure
secondary to systolic dysfunction which is not accompanied
by severe hypotension (Delle Karth et al 2003; Lehmann et
al 2004; Nieminen et al 2005). Use on patients with a systolic
blood pressure below 85 mmHg is not recommended
(Nieminen et al 2005).
Conclusion
Levosimendan is a new inodilator agent for the therapy of
end-stage heart failure, acting by calcium sensitization; it
also causes vasodilatation by opening K channels. However,
several recent studies showed different unexpected results,
contrary to mechanism of its action. Further clinical trials
may help to clarify its effects on mortality and use in clinical
practice.
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